A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT ...
A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT ...
Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria). Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see excl ...
A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT ...
A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT ...
Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria). Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see excl ...